RESULTS Act

On September 10, 2025, Representative Richard Hudson (R-NC) introduced H.R. 5269, the RESULTS Act, in the 119th Congress. The bill was referred to both the Energy and Commerce and Ways and Means Committees. It is in the earliest legislative stage — no hearings, markup, or floor votes have occurred. The bill's purpose is to amend the Social Security Act to improve data collection for the private payor-based fee schedule used to set Medicare payment rates for clinical diagnostic lab tests, aiming to provide long-term rate stability. The bill does not authorize or appropriate any specific funding amount. It modifies data submission requirements and data source standards — a regulatory and data standardization bill, not a spending bill. Actual Medicare payment rates would still be set through the existing administrative process using data collected under this updated framework; no direct financial transfer occurs from this legislation. The primary affected entities are publicly traded clinical lab companies Labcorp ($LH) and Quest Diagnostics ($DGX), as Medicare lab test revenue is material to both. However, at this early stage — bill text still in committee, no CBO score, no budget impact — the market impact is negligible. The bill's 77 bipartisan cosponsors and companion Senate bill (S. 2761) indicate broad support, but the legislative path requires full committee approval, House passage, Senate passage, and presidential action — a multi-year timeline at best. Real market data from Yahoo Finance shows LH at $259 (52-week range: $235.81–$293.72) with a 30-day decline of -2.93%. DGX is at $190.19 (52-week range: $164.65–$213.50) with a 30-day decline of -2.95%. Both stocks have weakened in the last week (LH -1.82%, DGX -3.1%), consistent with broader market conditions rather than this specific bill. Any material market impact from the RESULTS Act requires significant advancement through the legislative process. The earliest actionable milestone would be a committee markup or CBO score showing a net effect on Medicare spending or lab industry revenues. As of today, April 30, 2026, the bill remains in procedural limbo.